How to control pain in patients with pancreatic cancer?

Share This Post

Pancreatic cancer can invade and press nerves near the pancreas, which may cause abdominal or back pain in patients with pancreatic cancer. Pain specialists can help develop pain relief plans.

For most patients, morphine or similar drugs (opioids) can help control pain. But many people worry that these drugs will be addictive, but studies have shown that if patients take the doses prescribed by doctors, then the probability of patients being addicted to this drug is extremely low.

Analgesic drugs are best when taken regularly, but they are less effective if used only when the pain is severe. Several long-acting morphine and other opioids are in pill form and only need to be taken once or twice a day. There is also a long-acting drug fentanyl, which is used as a patch every 3 days. The common side effects of these drugs are nausea and drowsiness, which tend to improve over time. Constipation is a common side effect, and most patients need to take laxatives every day.

In addition, the doctor may block the nerves near the pancreas by using anesthetics or nerve-damaging drugs. This process is accomplished by passing the needle through the skin or using an endoscope (a long, soft tube that runs down the throat through the stomach). In addition, the use of chemotherapy and / or radiotherapy treatment can reduce pain by reducing the size of the tumor.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy